Yes. Senator Collins has authored and supported bipartisan drug-pricing measures, including a 2018 law banning pharmacy gag clauses, provisions to improve generic drug competition signed into law as part of the FDA Reauthorization Act, and the INSULIN Act – a bipartisan proposal to cap insulin costs at $35 per month for privately insured Americans, currently before the Senate.
What Collins has done on prescription drug costs:
- Pharmacy Gag Clause Prohibition, 2018: Collins authored and was signed into law in October 2018. This prohibited pharmacists from being contractually barred from telling patients about lower-cost drug options.
- FDA Reauthorization Act – Generic Competition Provisions: Collins co-authored provisions with Sen. Claire McCaskill. Signed into law.
- INSULIN Act (introduced 2022; reintroduced 2023 and March 2026): Co-introduced with Sen. Jeanne Shaheen. It would cap insulin at $35 per month for Americans with private and employer insurance. Currently before the Senate. Endorsed by the American Diabetes Association, Breakthrough T1D, and the Endocrine Society.
Why does this matter?
More than 37 million Americans have diabetes. Collins co-chairs the Senate Diabetes Caucus and has led prescription drug affordability work for more than a decade.